Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency

Background Novel messenger RNA vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV-2) have been vital in resolving the coronavirus disease-2019 (COVID-19) pandemic. Detection of neutralizing antibodies (NAbs) against the SARS-CoV-2 spike protein (S) confirms immunogenicity with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maaz Jalil DO, Marija Rowane OMS, Jayanth Rajan OMS, Robert Hostoffer DO, LhD, MSMEd, MBA, FACOP, FAAP, FACOI, FCCP
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Otorhinolaryngology RF1-547 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/4243f672b7ef4321b6b66bcfbbf04083
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4243f672b7ef4321b6b66bcfbbf04083
record_format	dspace
spelling	oai:doaj.org-article:4243f672b7ef4321b6b66bcfbbf040832021-11-30T23:35:57ZSuccessful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency2152-656710.1177/21526567211056239https://doaj.org/article/4243f672b7ef4321b6b66bcfbbf040832021-11-01T00:00:00Zhttps://doi.org/10.1177/21526567211056239https://doaj.org/toc/2152-6567Background Novel messenger RNA vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV-2) have been vital in resolving the coronavirus disease-2019 (COVID-19) pandemic. Detection of neutralizing antibodies (NAbs) against the SARS-CoV-2 spike protein (S) confirms immunogenicity with high sensitivity and specificity. Few recent studies with primary and secondary immunodeficient cohorts present adequate or reduced antibody response. We describe the first reported successful response to anti-SARS-CoV-2 S antibody post-vaccination in magnesium transporter 1 (MAGT1) gene deficiency, more commonly recognized as x-linked immunodeficiency with magnesium defect, Epstein-Barr Virus infection, and neoplasia (XMEN). Case Presentation We present a 30-year-old male with selective anti-polysaccharide antibody deficiency, peripheral blood CD5 + /CD19 + B-cell predominance (97%), MAGT1 mutation, and reduced CD16 + CD56 + natural killer- and/or CD8 + T-cell receptor, Group 2, Member D expression. His initial immunological evaluation revealed all seronegative post-vaccination antibody titers but clinically adequate response to protein antigens tetanus and diphtheria anti-toxoids. COVID-19 vaccination and associated serology antibody testing was recommended at this office visit. Anti-SARS-CoV-2 immunoglobulin (Ig)M and IgG antibodies before and after the first BNT162b2 mRNA COVID-19 vaccine doses, as well as nucleocapsid antibody, were negative. S protein total antibody was reactive after the second dose. Discussion Robust immunological sequelae post-COVID-19 vaccination in the general population are well-documented in the recent literature. Few studies have evaluated COVID-19 vaccination antibody response in immunodeficient patients. The majority positive anti-S antibody detection in most primary immunodeficient (PID) patients among the few studies in the literature, such as the present case, support the safety and efficacy of mRNA COVID-19 vaccination in immunodeficient patients, although larger scale studies are needed. Conclusion We demonstrate successful vaccination in the PID MAGT1 deficiency in this first reported case of reactive anti-S antibody post-COVID-19 vaccination.Maaz Jalil DOMarija Rowane OMSJayanth Rajan OMSRobert Hostoffer DO, LhD, MSMEd, MBA, FACOP, FAAP, FACOI, FCCPSAGE PublishingarticleOtorhinolaryngologyRF1-547Immunologic diseases. AllergyRC581-607ENAllergy & Rhinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Otorhinolaryngology RF1-547 Immunologic diseases. Allergy RC581-607
spellingShingle	Otorhinolaryngology RF1-547 Immunologic diseases. Allergy RC581-607 Maaz Jalil DO Marija Rowane OMS Jayanth Rajan OMS Robert Hostoffer DO, LhD, MSMEd, MBA, FACOP, FAAP, FACOI, FCCP Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
description	Background Novel messenger RNA vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV-2) have been vital in resolving the coronavirus disease-2019 (COVID-19) pandemic. Detection of neutralizing antibodies (NAbs) against the SARS-CoV-2 spike protein (S) confirms immunogenicity with high sensitivity and specificity. Few recent studies with primary and secondary immunodeficient cohorts present adequate or reduced antibody response. We describe the first reported successful response to anti-SARS-CoV-2 S antibody post-vaccination in magnesium transporter 1 (MAGT1) gene deficiency, more commonly recognized as x-linked immunodeficiency with magnesium defect, Epstein-Barr Virus infection, and neoplasia (XMEN). Case Presentation We present a 30-year-old male with selective anti-polysaccharide antibody deficiency, peripheral blood CD5 + /CD19 + B-cell predominance (97%), MAGT1 mutation, and reduced CD16 + CD56 + natural killer- and/or CD8 + T-cell receptor, Group 2, Member D expression. His initial immunological evaluation revealed all seronegative post-vaccination antibody titers but clinically adequate response to protein antigens tetanus and diphtheria anti-toxoids. COVID-19 vaccination and associated serology antibody testing was recommended at this office visit. Anti-SARS-CoV-2 immunoglobulin (Ig)M and IgG antibodies before and after the first BNT162b2 mRNA COVID-19 vaccine doses, as well as nucleocapsid antibody, were negative. S protein total antibody was reactive after the second dose. Discussion Robust immunological sequelae post-COVID-19 vaccination in the general population are well-documented in the recent literature. Few studies have evaluated COVID-19 vaccination antibody response in immunodeficient patients. The majority positive anti-S antibody detection in most primary immunodeficient (PID) patients among the few studies in the literature, such as the present case, support the safety and efficacy of mRNA COVID-19 vaccination in immunodeficient patients, although larger scale studies are needed. Conclusion We demonstrate successful vaccination in the PID MAGT1 deficiency in this first reported case of reactive anti-S antibody post-COVID-19 vaccination.
format	article
author	Maaz Jalil DO Marija Rowane OMS Jayanth Rajan OMS Robert Hostoffer DO, LhD, MSMEd, MBA, FACOP, FAAP, FACOI, FCCP
author_facet	Maaz Jalil DO Marija Rowane OMS Jayanth Rajan OMS Robert Hostoffer DO, LhD, MSMEd, MBA, FACOP, FAAP, FACOI, FCCP
author_sort	Maaz Jalil DO
title	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
title_short	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
title_full	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
title_fullStr	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
title_full_unstemmed	Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
title_sort	successful anti-sars-cov-2 spike protein antibody response to vaccination in deficiency
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/4243f672b7ef4321b6b66bcfbbf04083
work_keys_str_mv	AT maazjalildo successfulantisarscov2spikeproteinantibodyresponsetovaccinationindeficiency AT marijarowaneoms successfulantisarscov2spikeproteinantibodyresponsetovaccinationindeficiency AT jayanthrajanoms successfulantisarscov2spikeproteinantibodyresponsetovaccinationindeficiency AT roberthostofferdolhdmsmedmbafacopfaapfacoifccp successfulantisarscov2spikeproteinantibodyresponsetovaccinationindeficiency
_version_	1718406197843853312

Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency

Ejemplares similares